Background: type 1diabetes (T1DM) is a form of diabetes mellitus that results from  autoimmune  destruction of insulin-producing beta cells of the pancreas, leading to permanent insulin deficiency ,categorized as either being positive or negative for various auto antibodies related to pancreatic function .An anti glutamic acid decarboxylase autoantibody(Anti-GAD) is recognized as one of the major serological markers for type 1 diabetes mellitus.

Objectives: to determine the prevalence of the immunological marker  (Anti-GAD) among a sample of type1diabetus mellitus patients and to identify some factors that might be associated with its seroposivity.

Method:

Background: Glycemic control and prevention of secondary complications are the most important aims of using pharmacological treatments in diabetes mellitus. Due to the high incidence of inadequate response to insulin and, we try to evaluate the effects of adjunct use of silymarin with insulin on glycemic control, lipid profile and renal function in type 1 diabetes mellitus patients.
Patients and Methods: Placebo-controlled, doubled blinded clinical trial method is utilized through which 60 type 1 DM patients allocated into two groups, 30 patients treated with insulin and silymarin 400 mg/day in two divided doses, while the other 30 patients treated with insulin and placebo for 60 days. Fasting serum gluco

Background: Interleukin-6 (IL-6) is a cytokine that has several functions, including stimulating growth and inhibiting cell death. It has the potential to operate as a biomarker for the accurate prediction of disease severity and activity, platelets-rich plasma was used in the treatment of oral lichen planus and can change the salivary IL-6 level.

Objectives: To study the clinical outcome of intralesional platelets-rich plasma in patients with oral lichen planus and to measure salivary IL-6 levels before and after the treatment with platelets-rich plasma were the aims of this study.

Subjects and Methods: In this clinical trial, for each patient a standardi

Background; Hyperlipoproteinemia (HLP)  are divided in primary and secondary subtypes. Primary HLP is usually due to genetic causes. Secondary HLP is resulting from another underlying disorder such as diabetes mellitus that leads to alterations in plasma lipid and lipoprotein metabolism, HLP may be idiopathic .

Patients and Methods; Ninety male individuals (age 30-45)years were enrolled in this study which were divided into three groups as follows:- (G1) consist of 30 healthy male individuals as a control group, (G2) consist of  30 male patients with (HLP) without any other disease  (15 of them were HLP1,the other were HLP11), (G3) consist of 30 male patients with DM2 without any o

     Urotensin-II (UII), a pluripotent vasoactive cyclic peptide, exhibits the progression of cardiovascular diseases and the glucose metabolic disorder of insulin resistance. Type 2 Diabetes Mellitus (T2DM) is entirely associated with insulin resistance. This study aimed to demonstrate the association of UII with insulin resistance in diabetic and non-diabetic subjects. A total of 73 male and female subjects aged 40-60 years were recruited in this case-control study. They included 35 non- diabetic subjects with a body mass index of (BMI) ≤ 25 and 38 patients with Diabetes Mellitus and BMI ≥ 25. UII levels were assessed beside other vasoactive and clinical parameters.     The results re

Endothelin-I (ET-I) is one of the potent vasoconstrictors secreted from endothelial cells when needed. Many studies revealed the elevation of serum ET-I with human diabetes and microangiopathies. Since insulin resistance is a case of mixed diabetic and pre-diabetic cases, many risk factors beyond obesity and inflammation are proposed. The current study aims to demonstrate the association between serum ET-I and asymmetric dimethylarginine (ADMA) and insulin resistance in type 2 diabetes mellitus (T2DM). Sera of 73 subjects were enrolled currently (control= 35 subjects, and 38 with T2DM for more than 7 years), aged (40-60) years old, with distinct body mass index (BMI) ≤ 25 for control volunteers and (BMI) ≥ 25 for obesity and diabetes

Background: Diabetic patients have been reported to be more susceptible to gingivitis and periodontitis than healthy subjects. Many intracellular enzymes like (alkaline phosphatase- (ALP), aspartate aminotransferase- (AST) and alanine aminotransferase- (ALT) that are released outside cells into the gingival crevicular fluid (GCF) and saliva after destruction of periodontal tissue during periodontitis. This study was conducted to determine the periodontal health status and the levels of salivary enzymes (ALP, AST and ALT) of the study and control groups and to correlate the levels of these enzymes with clinical periodontal parameters in each study group. Subjects, Materials and Methods: One hundred subjects were enrolled in the study, with a

Background: Diabetes mellitus consists of a group of diseases characterized by abnormally high blood glucose levels. Glycated haemoglobin (HbA1c) is a form of haemoglobin used to identify the average concentration of plasma glucose over prolonged periods of time. It is formed in a non-enzymatic pathway by normal exposure of hemoglobin to high levels of plasma glucose, The main alterations observed in the saliva of Type 1 diabetic patients are hyposalivation and alteration in its composition, particularly those related to the levels of glucose. The aim of the present study was to assess the effect of Glycated haemoglobin level on the level of salivary glucose which may have an effect on oral health condition. Materials and methods